Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	Time-to-event to achieve WHO level ≤3	30 days	Evaluation of the time-to-event to achieve a WHO level score ≤3
Primary	Death rate	30 days	Evaluation of the time-to-event where all-cause mortality occurs
Secondary	Hospital discharge to chronic palliative care	30 days	Measured incidence of hospital discharge to chronic palliative care
Secondary	Hospital discharge with no additional medical care	30 days	Measured incidence of hospital discharge with no additional medical care required
Secondary	Related adverse events (AEs) and serious adverse events (SAEs)	90 days	Measured incidence of related AEs and SAEs
Secondary	Study discontinuation due to related AEs or SAEs	90 days	Measured incidence of study discontinuation due to related AEs or SAEs
Other	Pharmacokinetic (PK) endpoint-Assess area under the curve	14 days	Measure area under the curve (AUC) for famotidine and celecoxib combination in 10 patients per group
Other	Pharmacokinetic (PK) endpoint-Assess time to maximum plasma concentration	14 days	Measure time to maximum plasma concentration (tmax) for famotidine and celecoxib combination in 10 patients per group
Other	Pharmacokinetic (PK) endpoint-Assess maximum serum concentration	14 days	Measure maximum serum concentration (Cmax) for famotidine and celecoxib combination in 10 patients per group
Other	Exploratory endpoint-Incidence of symptom reduction	14 days	Cumulative incidence of clinically significant symptom reduction (severity and duration) using COVID-19 Symptom Score
Other	Exploratory endpoint-Incidence of clinical improvement	14 days	Cumulative incidence of clinically significant symptom reduction (severity and duration) using WHO Ordinal Scale for Clinical Improvement
Other	Special Assessment - High-resolution computed tomography (HRCT), 20 patients/group, change from baseline	Study Day 1 (baseline), Day 16 (discharge), 30 days after first dose, and 90 days after first dose	HRCT scan of the chest
Other	Special Assessment - Total lung capacity (TLC), 20 patients/group, change from baseline	Study Day 1 (baseline), 16 (discharge), 30 days after first dose, and 90 days after first dose	TLC
Other	Special Assessment - Prostaglandin E2 (PGE2), 20 patients/group, change from baseline	Study Day 1 (baseline), 16 (discharge), 30 days after first dose, and 90 days after first dose	PGE2 testing
Other	Special Assessments - Urinalysis, 20 patients/group, change from baseline	Study Day 1 (baseline) and 16 (discharge)	Urinalysis

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05085574/registered

API reference For AI assistants